The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase I study to evaluate toxicity and feasibility of intratumoral injection of alpha-gal glycolipids in patients with advanced melanoma.
Mark R. Albertini
Research Funding - Agalimmune
Erik Ranheim
No relevant relationships to disclose
Cindy Zuleger
Research Funding - Agalimmune
Paul M. Sondel
No relevant relationships to disclose
Jacquelyn A Hank
No relevant relationships to disclose
Alan Bridges
No relevant relationships to disclose
Michael Newton
No relevant relationships to disclose
Thomas McFarland
No relevant relationships to disclose
Jennifer Collins
No relevant relationships to disclose
Erin Clements
No relevant relationships to disclose
MaryBeth Henry
No relevant relationships to disclose
Heather B. Neuman
No relevant relationships to disclose
Sharon M. Weber
No relevant relationships to disclose
Giles Francis Whalen
No relevant relationships to disclose
Uri Galili
Consultant or Advisory Role - Agalimmune
Stock Ownership - Agalimmune
Research Funding - Agalimmune
Other Remuneration - Agalimmune